
Merck to Test Keytruda With an HDAC Inhibitor
With an aim to grab band-width in the shared PD-1 space, Merck has partnered with Syntax to conduct combination studies of Keytruda with Entinostat in melanoma and lung cancer patients.
Merck has reached an agreement to test
Entinostat is in the same class as Novartis'
Link to the complete article on PMLive:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.